

Frank Danna, III

10 November 2019

Securities and Exchange Commission
c/o Vanessa Countryman, Secretary
100 F Street, NE
Washington, DC 20549-0609




RE: File No. S7-14-19

Dear Sir/Ma'am,

Thank you for the opportunity to comment on recent proposed rule changes to 17 CFR Parts 230 and 240. I would ask that you reconsider these changes due my personal experience trading these products. I think that trading these is clearly risky, traders should know that. Because it is risky, this doesn't necessarily mean it should further be regulated. OTC companies, which are already operating within the law, should be free to conduct business without further bureaucracy. This only costs them more money, which will further drive up the cost of the already exorbitant OTC fees that I pay. It is extremely difficult (and costly) trading these....I implore you not to add more rules and regulations for everyone to follow.

Very Sincerely,

A handwritten signature in black ink, appearing to read "Frank Danna, III".

Frank Danna, III